Abstract

MAZZOLINI, Guillermo D  and  MALVICINI, Mariana. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy: Trends and perspectives. Medicina (B. Aires) [online]. 2018, vol.78, n.1, pp.29-32. ISSN 0025-7680.

Hepatocellular carcinoma (HCC) is the second cause of cancer-related death in the world and is the main cause of death in cirrhotic patients. Unfortunately, the incidence of HCC has grown significantly in the last decade. Curative treatments such as surgery, liver transplantation or percutaneous ablation can only be applied in less than 30% of cases. The multikinase inhibitor sorafenib is the first line therapy for advanced HCC. Regorafenib is the standard of care for second-line patients. However, novel and more specific potent therapeutic approaches for advanced HCC are still needed. The liver constitutes a unique immunological microenvironment, although anti-tumor immunity seems to be feasible with the use of checkpoint inhibitors such as nivolumab. Efficacy may be further increased by combining checkpoint inhibitors or by applying loco-regional treatments. The success of immune checkpoint blockade has renewed interest in immunotherapy in HCC.

Keywords : Hepatocellular carcinoma; Immunostimulatory monoclonal antibodies; Cytotoxic T-lymphocyte antigen 4 (CTLA-4); Programmed cell death 1 ligand (PD1-L); Tumor-infiltrating lymphocytes.

        · abstract in Spanish     · text in English     · English ( pdf )